Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Long-Term Investments (2017 - 2025)

Bioceres Crop Solutions' Long-Term Investments history spans 8 years, with the latest figure at $39.4 million for Q2 2025.

  • For Q2 2025, Long-Term Investments fell 1.04% year-over-year to $39.4 million; the TTM value through Jun 2025 reached $39.4 million, down 1.04%, while the annual FY2025 figure was $39.4 million, 1.04% down from the prior year.
  • Long-Term Investments for Q2 2025 was $39.4 million at Bioceres Crop Solutions, down from $39.8 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $39.8 million in Q2 2024 and bottomed at $444870.0 in Q2 2022.
  • The 4-year median for Long-Term Investments is $35.0 million (2021), against an average of $27.6 million.
  • The largest annual shift saw Long-Term Investments increased 24.36% in 2021 before it crashed 98.55% in 2022.
  • A 4-year view of Long-Term Investments shows it stood at $30.7 million in 2021, then plummeted by 98.55% to $444870.0 in 2022, then surged by 8843.37% to $39.8 million in 2024, then dropped by 1.04% to $39.4 million in 2025.
  • Per Business Quant, the three most recent readings for BIOX's Long-Term Investments are $39.4 million (Q2 2025), $39.8 million (Q2 2024), and $444870.0 (Q2 2022).